ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology company specializing in the production of custom antibodies and related services. Headquartered in Fargo, North Dakota, the company operates in the United States, Canada, Europe, and internationally. Its extensive service offerings include B cell sorting, phage display production, transgenic animal models, and various antibody engineering techniques. The company has developed a reputation for its advanced capabilities in antibody discovery and development, leveraging systems biology, multi-omics modeling, and artificial intelligence to enhance efficiency and accuracy. ImmunoPrecise Antibodies engages in collaborations with academic and research institutions, including partnerships aimed at developing antibody-based tests for COVID-19 and neutralizing antibodies against SARS-CoV-2. Founded in 1989, the company continues to contribute to the advancement of novel biologics and therapeutic solutions for challenging diseases.
Carterra- LSA platform is a versatile, fully integrated, high throughput monoclonal antibody (mAb) characterization platform that combines patented flow printing microfluidics with high throughput surface plasmon resonance (SPR) detection to deliver up to 100x the data in 10% of the time and with 1% of the sample requirements and consumable costs of other systems.
BioStrand
Acquisition in 2022
BioStrand, founded in 2019 and based in Diepenbeek, Belgium, specializes in advanced technologies for genomic variation identification. The company has developed a unique methodology that enhances the detection of similarities and variations in genetic data, including DNA, RNA, and proteins. By integrating structural 3D information through its proprietary HYFTSTM technology, BioStrand offers unprecedented accuracy in analyzing genetic data. This innovative approach is poised to drive advancements in precision medicine, drug development, and agricultural applications, enabling more effective detection of patterns and profiles critical for understanding diseases and biological processes.
ModiQuest B.V.
Acquisition in 2018
ModiQuest specializes in the generation of monoclonal antibodies against difficult target antigens for R&D, diagnostic and therapeutic applications. Using its proprietary ModiFuse™ (hybridoma electrofusion), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest can generate very large panels of monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human, as well as transgenic animals harboring the human immunoglobulin (antibody) gene repertoire, against virtually any target. Besides antibody lead generation, ModiQuest also provides extensive antibody development and optimization procedures, such as affinity maturation, humanization, stable cell line generation and antibody production in transient and stable mammalian cell systems.
U-Protein Express
Acquisition in 2017
U-Protein Express B.V. is a contract research organization based in Utrecht, the Netherlands, specializing in the production and marketing of recombinant proteins and antibodies for research and pre-clinical applications. Established in 2007, the company offers a diverse product portfolio that includes antibodies, complement proteins, cytokines, enzymes, hormones, and oncology-related products. U-Protein Express provides services such as protein purification, recombinant antibody development, and monoclonal antibody generation, utilizing advanced rPEX technology to efficiently produce difficult-to-express proteins, including Fc-fusion proteins and bi-specific antibodies. The organization has successfully produced over 5,000 different recombinant antibodies and proteins for clients in the biotech, pharmaceutical, and academic sectors, boasting a high success rate. U-Protein Express operates as a subsidiary of ImmunoPrecise Antibodies Ltd., which operates from laboratories in Canada.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.